9min read
Industry News
ASCO 2026 studies from Cleveland Clinic, Penn Medicine, and Roswell Park suggest GLP-1s may reduce cancer progression — observational findings analyzed.
9min read
Peptide Guide
A 29-amino-acid synthetic GHRH fragment studied for growth hormone axis modulation, pediatric GHD research, and adult GH research applications.
9min read
Comparison
DSIP vs Epitalon compared head-to-head — distinct mechanisms, distinct research applications, and how to choose between them for sleep and circadian research.
6min read
Industry News
Preview of the ADA 86th Scientific Sessions in New Orleans (June 5-8, 2026) — TRIUMPH-1 detailed data, CagriSema, zenagamtide, and the cardiometabolic pipeline.
8min read
Peptide Guide
A Russian-developed tetrapeptide studied for pineal-melatonin modulation, circadian rhythm regulation, telomerase activity, and aging research applications.
8min read
Industry News
TRIUMPH-1 Phase 3 results announced May 21, 2026 show Retatrutide delivering up to 30% body weight reduction at 104 weeks — the largest documented in any GLP-1
8min read
Industry News
The FDA’s July 2026 PCAC hearing will review seven peptides including BPC-157, TB-500, and Semax for potential return to the Section 503A compounding list.
7min read
Peptide Guide
A nonapeptide originally identified for sleep-inducing effects in rabbit brain studies, studied across sleep architecture, stress, analgesia, and CNS research.
9min read
Comparison
Selank vs Semax compared head-to-head — distinct lineages (tuftsin vs ACTH 4-10), distinct mechanisms (anxiolytic vs nootropic), shared cluster identity.